سعر فولوتين 20 مجم / مل فيال وريد 2026

Pralatrexate 20 mg/mL solution in a single vial for intravenous use, a folate analogue antimetabolite for relapsed or refractory peripheral T-cell lymphoma.

• Relapsed or refractory peripheral T-cell lymphoma (PTCL); US accelerated approval based on overall response rate.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>35%): mucositis, thrombocytopenia, nausea and fatigue.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None (US label lists no contraindications).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myelosuppression (thrombocytopenia, neutropenia, anaemia): give folic acid and vitamin B12, monitor blood counts and omit or reduce doses based on ANC and platelets.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Mucositis: monitor at least weekly; omit or reduce dose for grade 2 or higher.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe, potentially fatal dermatologic reactions including skin exfoliation, ulceration and toxic epidermal necrolysis; monitor and withhold or discontinue by severity.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Probenecid; NSAIDsProbenecid increased pralatrexate plasma concentrations; avoid coadministration with probenecid or NSAIDs, or monitor for increased adverse reactions if unavoidable.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on animal data and mechanism; embryotoxic and fetotoxic in rats and rabbits at about 1.2% of the clinical dose. Females should use effective contraception during treatment and for 6 months after the last dose (males with female partners: 3 months).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; advise not to breastfeed during treatment and for 1 week after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pralatrexate: Competitively inhibits dihydrofolate reductase and folylpolyglutamyl synthetase, depleting thymidine and other molecules whose synthesis depends on one-carbon transfer.